ИнТОР - Репозиторијум Институтa „Торлак“
Институт за вирусологију, вакцине и серуме „Торлак“
    • English
    • Српски
    • Српски (Serbia)
  • Српски (ћирилица) 
    • Енглески
    • Српски (ћирилица)
    • Српски (латиница)
  • Пријава
Преглед записа 
  •   ИнТОР
  • Torlak
  • Radovi istraživača / Researchers’ publications
  • Преглед записа
  •   ИнТОР
  • Torlak
  • Radovi istraživača / Researchers’ publications
  • Преглед записа
JavaScript is disabled for your browser. Some features of this site may not work without it.

Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial

Thumbnail
2016
postprint-Lactobacillus_helveticus_lafti_acc_2016.pdf (491.0Kb)
Аутори
Michalickova, Danica
Minić, Rajna
Dikić, Nenad
Anđelković, Marija
Kostić-Vučićević, Marija
Stojmenović, Tamara
Nikolić, Ivan
Đorđević, Brižita
Чланак у часопису (Рецензирана верзија)
Метаподаци
Приказ свих података о документу
Апстракт
A randomized, double-blind, placebo-controlled study was conducted to evaluate if Lactobacillus helveticus Lafti L10 (Lallemand Health Solutions, Montreal, Que., Canada) supplementation during 14 weeks in winter can influence the duration, severity, and incidence of upper respiratory tract illness (URTI), as well as to monitor different immune parameters in the population of elite athletes. Before and after the treatment, cardiopulmonary testing and self-rated state of moods evaluation (by Profile of Mood States questionnaire) were performed and blood samples were collected. Thirty-nine elite athletes were randomized either to the placebo (n = 19) or the probiotic (n = 20) group. The probiotic group received L. helveticus Lafti L10, 2 x 10(10) Colony Forming Units. Lafti L10 significantly shortened the URTI episode duration (7.25 +/- 2.90 vs. 10.64 +/- 4.67 days, p = 0.047) and decreased the number of symptoms in the probiotic group (4.92 +/- 1.96 vs. 6.91 +/- 1.22, p = 0.035). Severit...y and incidence of URTI did not differ between the treatments. There were no significant changes in leukocyte subpopulation abundance, transforming growth factor-beta serum levels, level of interleukin-10 secreted from peptidoglican stimulated peripheral blood mononuclear cells (PBMCs), interferon-gamma level secreted from concanavalin A-stimulated PBMCs or viability/proliferation of PBMCs upon antigen stimulation. Group effect for CD4+/CD8+ ratio was significant (F-[1,F-37] = 6.99, p = 0.020, eta(2) = 0.350); this difference was not significant at baseline, but was evident after 14 weeks (p = 0.02). A significant interaction effect was noted for self-rated sense of vigor (F-[1,F-37] = 11.76, p = 0.009, eta(2) = 0.595). Self-rated sense of vigor increased in the probiotic group (18.5 +/- 4.1 vs. 21.0 +/- 2.6, p = 0.012). Probiotic strain Lafti L10 can be a beneficial nutritional supplement for the reduction of URTI length in elite athletes.

Кључне речи:
Lactobacillus / upper respiratory tract illness (URTI) / CD4+/CD8+ratio / POMS
Извор:
Applied Physiology Nutrition and Metabolism, 2016, 41, 7, 782-789
Издавач:
  • Canadian Science Publishing, Ottawa
Финансирање / пројекти:
  • Lallemand Health Solutions, Montreal, Canada
  • Унапређење и развој хигијенских и технолошких поступака у производњи намирница животињског порекла у циљу добијања квалитетних и безбедних производа конкурентних на светском тржишту (RS-46009)
  • Алергени, антитела, ензими и мали физиолошки значајни молекули: дизајн, структура, функција и значај (RS-172049)
Напомена:
  • This is the peer-reviewed version of the following article: Michalickova, D.; Minić, R.; Dikić, N.; Anđelković, M.; Kostić-Vučićević, M.; Stojmenović, T.; Nikolić, I.; Đorđević, B. Lactobacillus Helveticus Lafti L10 Supplementation Reduces Respiratory Infection Duration in a Cohort of Elite Athletes: A Randomized, Double-Blind, Placebo-Controlled Trial. Applied Physiology Nutrition and Metabolism 2016, 41 (7), 782–789. https://doi.org/10.1139/apnm-2015-0541.
Повезане информације:
  • Друга верзија
    http://intor.torlakinstitut.com/handle/123456789/476

DOI: 10.1139/apnm-2015-0541

ISSN: 1715-5312

PubMed: 27363733

WoS: 000379430100013

Scopus: 2-s2.0-84977579626
[ Google Scholar ]
32
32
URI
http://intor.torlakinstitut.com/handle/123456789/607
Колекције
  • Radovi istraživača / Researchers’ publications
Институција/група
Torlak
TY  - JOUR
AU  - Michalickova, Danica
AU  - Minić, Rajna
AU  - Dikić, Nenad
AU  - Anđelković, Marija
AU  - Kostić-Vučićević, Marija
AU  - Stojmenović, Tamara
AU  - Nikolić, Ivan
AU  - Đorđević, Brižita
PY  - 2016
UR  - http://intor.torlakinstitut.com/handle/123456789/607
AB  - A randomized, double-blind, placebo-controlled study was conducted to evaluate if Lactobacillus helveticus Lafti L10 (Lallemand Health Solutions, Montreal, Que., Canada) supplementation during 14 weeks in winter can influence the duration, severity, and incidence of upper respiratory tract illness (URTI), as well as to monitor different immune parameters in the population of elite athletes. Before and after the treatment, cardiopulmonary testing and self-rated state of moods evaluation (by Profile of Mood States questionnaire) were performed and blood samples were collected. Thirty-nine elite athletes were randomized either to the placebo (n = 19) or the probiotic (n = 20) group. The probiotic group received L. helveticus Lafti L10, 2 x 10(10) Colony Forming Units. Lafti L10 significantly shortened the URTI episode duration (7.25 +/- 2.90 vs. 10.64 +/- 4.67 days, p = 0.047) and decreased the number of symptoms in the probiotic group (4.92 +/- 1.96 vs. 6.91 +/- 1.22, p = 0.035). Severity and incidence of URTI did not differ between the treatments. There were no significant changes in leukocyte subpopulation abundance, transforming growth factor-beta serum levels, level of interleukin-10 secreted from peptidoglican stimulated peripheral blood mononuclear cells (PBMCs), interferon-gamma level secreted from concanavalin A-stimulated PBMCs or viability/proliferation of PBMCs upon antigen stimulation. Group effect for CD4+/CD8+ ratio was significant (F-[1,F-37] = 6.99, p = 0.020, eta(2) = 0.350); this difference was not significant at baseline, but was evident after 14 weeks (p = 0.02). A significant interaction effect was noted for self-rated sense of vigor (F-[1,F-37] = 11.76, p = 0.009, eta(2) = 0.595). Self-rated sense of vigor increased in the probiotic group (18.5 +/- 4.1 vs. 21.0 +/- 2.6, p = 0.012). Probiotic strain Lafti L10 can be a beneficial nutritional supplement for the reduction of URTI length in elite athletes.
PB  - Canadian Science Publishing, Ottawa
T2  - Applied Physiology Nutrition and Metabolism
T1  - Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial
EP  - 789
IS  - 7
SP  - 782
VL  - 41
DO  - 10.1139/apnm-2015-0541
ER  - 
@article{
author = "Michalickova, Danica and Minić, Rajna and Dikić, Nenad and Anđelković, Marija and Kostić-Vučićević, Marija and Stojmenović, Tamara and Nikolić, Ivan and Đorđević, Brižita",
year = "2016",
abstract = "A randomized, double-blind, placebo-controlled study was conducted to evaluate if Lactobacillus helveticus Lafti L10 (Lallemand Health Solutions, Montreal, Que., Canada) supplementation during 14 weeks in winter can influence the duration, severity, and incidence of upper respiratory tract illness (URTI), as well as to monitor different immune parameters in the population of elite athletes. Before and after the treatment, cardiopulmonary testing and self-rated state of moods evaluation (by Profile of Mood States questionnaire) were performed and blood samples were collected. Thirty-nine elite athletes were randomized either to the placebo (n = 19) or the probiotic (n = 20) group. The probiotic group received L. helveticus Lafti L10, 2 x 10(10) Colony Forming Units. Lafti L10 significantly shortened the URTI episode duration (7.25 +/- 2.90 vs. 10.64 +/- 4.67 days, p = 0.047) and decreased the number of symptoms in the probiotic group (4.92 +/- 1.96 vs. 6.91 +/- 1.22, p = 0.035). Severity and incidence of URTI did not differ between the treatments. There were no significant changes in leukocyte subpopulation abundance, transforming growth factor-beta serum levels, level of interleukin-10 secreted from peptidoglican stimulated peripheral blood mononuclear cells (PBMCs), interferon-gamma level secreted from concanavalin A-stimulated PBMCs or viability/proliferation of PBMCs upon antigen stimulation. Group effect for CD4+/CD8+ ratio was significant (F-[1,F-37] = 6.99, p = 0.020, eta(2) = 0.350); this difference was not significant at baseline, but was evident after 14 weeks (p = 0.02). A significant interaction effect was noted for self-rated sense of vigor (F-[1,F-37] = 11.76, p = 0.009, eta(2) = 0.595). Self-rated sense of vigor increased in the probiotic group (18.5 +/- 4.1 vs. 21.0 +/- 2.6, p = 0.012). Probiotic strain Lafti L10 can be a beneficial nutritional supplement for the reduction of URTI length in elite athletes.",
publisher = "Canadian Science Publishing, Ottawa",
journal = "Applied Physiology Nutrition and Metabolism",
title = "Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial",
pages = "789-782",
number = "7",
volume = "41",
doi = "10.1139/apnm-2015-0541"
}
Michalickova, D., Minić, R., Dikić, N., Anđelković, M., Kostić-Vučićević, M., Stojmenović, T., Nikolić, I.,& Đorđević, B.. (2016). Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial. in Applied Physiology Nutrition and Metabolism
Canadian Science Publishing, Ottawa., 41(7), 782-789.
https://doi.org/10.1139/apnm-2015-0541
Michalickova D, Minić R, Dikić N, Anđelković M, Kostić-Vučićević M, Stojmenović T, Nikolić I, Đorđević B. Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial. in Applied Physiology Nutrition and Metabolism. 2016;41(7):782-789.
doi:10.1139/apnm-2015-0541 .
Michalickova, Danica, Minić, Rajna, Dikić, Nenad, Anđelković, Marija, Kostić-Vučićević, Marija, Stojmenović, Tamara, Nikolić, Ivan, Đorđević, Brižita, "Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial" in Applied Physiology Nutrition and Metabolism, 41, no. 7 (2016):782-789,
https://doi.org/10.1139/apnm-2015-0541 . .

DSpace software copyright © 2002-2015  DuraSpace
О репозиторијуму ИнТОР | Пошаљите запажања

OpenAIRERCUB
 

 

Комплетан репозиторијумИнституцијеАуториНасловиТемеОва институцијаАуториНасловиТеме

Статистика

Преглед статистика

DSpace software copyright © 2002-2015  DuraSpace
О репозиторијуму ИнТОР | Пошаљите запажања

OpenAIRERCUB